Neuroendocrinal Tumors : A Case of Mistaken Identity. Mohamed Abdulla M.D. Professor of Clinical Oncology, Kasr El-Aini School of Medicine Cairo University.

Slides:

Advertisements

Similar presentations

Progress Against Stomach Cancer. 1980–1989 Progress Against Stomach Cancer 1980– : Combination chemotherapy improves outcomes for advanced stomach.

Advertisements

Case 20 Thomas J. Giordano, M.D., Ph.D.. History A 54-year old man with a past medical history of goiter for approximately 4 years was followed by ultrasound.

Triple negative breast cancer

Regional Perspectives on Renal Cell Carcinoma Mohamed Abdulla M.D. Professor of Clinical Oncology Cairo University AfME. September 17 th 2010W:

Follicular lymphoma Optimal primary therapy and consolidation ? Seminars in Hematological Oncology * Israel, April M. Dreyling, Dept. of Medicine.

Management of Acoustic Neuroma NEMROCK Experience Mohamed Abdulla (M.D.) Ass. Professor of Clinical Oncology Kasr El-Aini School of Medicine.

Management of Gastroenteropancreatic Neuroendocrine Tumour: an update

Yao 1 Neuroendocrine Tumors James C. Yao, MD Associate Professor Deputy Chairman, Gastrointestinal Medical Oncology University of Texas M. D. Anderson.

Pancreatic NET What’s new? George Fisher, MD PhD Pamela Kunz, MD Division of Oncology Stanford University Medical School March 29, 2009.

Dr.vahedian ardakani Medical oncologist 91/11/5. Neuroendocrine tumors (NETs) are derived from the diffuse neuroendocrine system, which is made up of.

Radioactive Iodine Refractory Patients : Definition and Treatment of Radioactive Iodine Refractory Thyroid Cancer Patients 방사성 옥소치료에 내성을 가진 갑상선암의 진단과 치료에.

Hepatic Ablation Therapies Before Systemic Therapy Jordan D. Berlin, M.D. Ingram Professor of Cancer Research Co-director, GI Oncology Director, Phase.

What’s new in NETs? Lucy Wall Consultant Medical Oncologist Ann Edgar Patient Forum 10 th May 2013.

Emerging Treatment Options in the Management of Neuroendocrine Tumors

Julie R. Gralow, M.D. Director, Breast Medical Oncology, Seattle Cancer Care Alliance Professor, Medical Oncology, University of Washington School of Medicine.

Systemic Approach to Advanced Colon Cancer Mohamed Abdulla (M.D.) Ass. Prof. Clinical Oncology Kasr El-Aini School of Medicine Cairo University April,

Luciano M. Vargas Jr. MD Jean Grem MD Lucienne Case RN Haley Armstrong Review & Update Neuroendocrine Tumor Management.

Case Presentation: Neuroendocrine Tumor in the Midgut

Clinical Trials The Way We Make Progress Against Disease.

Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.

Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology.

Joint Hospital Surgical Grand Round 21 st July, 2012 RH.

Palliative Chemotherapy Dr. Oscar S. Breathnach Consultant Medical Oncologist Palliative Care Multidisciplinary Study Day Beaumont Hospital Sept. 19 th,

Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of Medicine Amrita Institute of Medical Sciences Kochi, Kerala.

Living Beyond Breast Cancer Liver and Lung Metastases Workshop April 29, 2012 Paul B. Gilman, MDLankenau Medical Center.

Unit of Gastrenterology Unit of Endocrinology THEAGENIO Hospital, Thessaloniki Metastatic neuroendocrine tumor of the jejunum-ileum.

ΕΠΙΘΕΤΙΚΕΣ ΘΕΡΑΠΕΙΕΣ ΑΡΓΑ

Meeting goals Provide participants – Current status regarding Classification Diagnosis Management – Update on the latest developments in neuroendocrine.

Diagnosis and treatment of neuroendocrine tumors Dan Granberg.

Neuroendocrine Tumours – Current Treatments Mark WJ Strachan Metabolic Unit, Western General Hospital, Edinburgh.

GI-NEUROENDOCRINE TUMORS THERAPEUTIC APROACHES Chemotherapy: older and recent schemes Ilias Athanasiadis, MD Medical Oncologist Director of the Oncology.

Endocrinology Unit Pathophysiology Department Laikon General Hospital Case Presentation: Dr. Chatzellis Eleftherios MD Intern in Endocrinology.

Michael Birrer Ian McNeish New Developments in Biology and Targets of Epithelial Ovarian Cancer.

Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical.

CASE 1 65-year-old man No other diseases or previous surgeries July 2005: PSA 11.5 ng/ml; F/T: 9% After prostate biopsy revealing adenocarcinoma: RETROPUBIC.

Phase 2 study of the mTOR inhibitor RAD001 (everolimus) in combination with bevacizumab (avastin) in patients with sporadic and neurofibromatosis type.

“INTEGRAZIONE TRA TERAPIA CHIRURGICA E TERAPIA MEDICA” Camillo Porta, MD Medical Oncology I.R.C.C.S. San Matteo University Hospital Foundation, Pavia.

Neuroendocrine Tumours

Chapter 6 Cancer. Frequency and Significance Cancer is the 2 nd leading cause of death in the United States Obviously, the term cancer covers many types.

PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington.

Blood and Tissue Based Molecular Signatures in Predicting Prostate Cancer Progression Tarek A. Bismar, MD Professor, University of Calgary Departments.

Raafat R. Abdel-Malek, MD, FRCR Ass. Prof Clinical Oncology Cairo University, Egypt Efficacy & Toxicity of Sunitinib in mRCC patients in Egypt.

A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.

ESMO 2011 Breast Cancer BOLERO-2 Authors: CARE Faculty (Drs. Anil Joy and Sunil Verma) Date posted: October 12, 2011.

S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.

Carcinoid GI tumors Sasha Rabotin. Carcinoid tumors first described by Lubarsch Oberndorfer coined the term Karzinoide to indicate the carcinoma-like.

The University of Texas - MD Anderson Cancer Center

Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer V. Heinemann*, M. Haas & S. Boeck Annals of Oncology 24: 2484–2492,

Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.

LANCET 2011; 378: 2005–12 R3 Kim Dong Hyun / Prof. Chin Sang Ouk Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine.

What should patients with BRAF mutant melanoma receive as front line therapy? Antoni Ribas, M.D. Professor of Medicine Professor of Surgery Professor of.

Challenges for the treatment of breast cancer

RECURRENT METASTATIC LARGE CELL NEUROENDOCRINE CARCINOMA OF CAECUM

NET MASTERCLASS GI-NEUROENDOCRINE TUMORS: THERAPEUTIC APPROACHES: SYMPTOMATIC MANAGEMENT IOANNIS PILPILIDIS, MD, FEBGH GASTROENTEROLOGY – ONCOLOGY.

Peptide Receptor Radionuclide Therapy PRRT

Apoptosis Nov, 2008.

What Do We Still Need to Know?

Figure 5 Schematic illustration of different clinical trial designs

Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors

Program Goals. ESSENTIAL CONCEPTS IN THE USE OF SOMATOSTATIN ANALOGUES IN PATIENTS WITH NEUROENDOCRINE TUMORS.

Figure 1 Current treatments for PNETs

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Treatment Overview: The Multidisciplinary Team

Kjell E. Öberg, Jean–Claude Reubi, Dik J. Kwekkeboom, Eric P. Krenning

Martin M et al. Proc SABCS 2012;Abstract S1-7.

Types of biomarkers/biosignatures to be used for cardiovascular disease. Types of biomarkers/biosignatures to be used for cardiovascular disease. There.

Possible outcomes of therapeutic treatments using the spiral model.

Giulia Tarantola, Humanitas University

Presentation transcript:

Neuroendocrinal Tumors : A Case of Mistaken Identity. Mohamed Abdulla M.D. Professor of Clinical Oncology, Kasr El-Aini School of Medicine Cairo University. Alexandria – EGSSO – 24/06/2010

?

Objectives: Basic Information. Magnitude of The Problem. Pitfalls in Diagnosis. What is New in Therapeutic Strategies.

Origin & Classification:

Natural History: Cure Indolent Dismal Outcome Aggressive Resistant to ttt Indolent 1.Clinical Manifestations are Vague. 2.Advanced & Metastatic at Presentation. 3.Complete Surgical Removal is Questionable. 4.The Available Therapeutic Options are not Effective.

Staging & Survival: SEER Staging & Classification LocalizedRegional Extension to Surroundings Nodal DiseaseBoth Distant Yao et al. JCO. 2008, 26(18)

Staging & Survival: G Yao et al. JCO. 2008, 26(18)

Staging & Survival: G Yao et al. JCO. 2008, 26(18)

Neuroendocrinal Tumors: The Hassle

Neuroendocrinal Tumors: Yao et al. JCO. 2008, 26(18)

Neuroendocrinal Tumors: Yao et al. JCO. 2008, 26(18)

Neuroendocrinal Tumors: Yao et al. JCO. 2008, 26(18)

Neuroendocrinal Tumors: American Cancer Society. Cancer prevalence: how many people have cancer? Updated October 30, Accessed May 7, 2009.

Neuroendocrinal Tumors: Increased Incidence??Better Understanding??

Critical Biomarkers: 1. Plasma Chromogranin (CgA) A Measure of Endocrine Tissues. Non-Specific False Positive Results: Proton Pump Inhibitors. Atrophic Gastritis. Renal Impairment.

Critical Biomarkers: 2. Urinary 5-HIAA: Compromised Survival

Looking at Neuroendocrine Tumors: Octreoscan. SPECT/CT Hybrid Imaging. MIBG. CT/MRI. Endoscopic Ultrasound. Capsule Endoscopy.

Neuroendocrinal Tumors: Management:

Neuroendocrinal Tumors: Conventional Medical Treatment: Sterptozotocin. Anthracyclins. Flouroupyremidines. Dacarbazine.

Neuroendocrinal Tumors: Somatostatin analogues: sst1sst2sst3sst4sst5 Blocking of Hormone Synthesis Anti-proliferative Effect Symptomatic Relief 60% Tumor Shrinkage 5%

++ PFS (15.6 vs 5.9 months). SD in 67%. Functioning and Non-Functioning Tumors. Neuroendocrinal Tumors: Somatostatin analogues: PROMID Study (2009):

Neuroendocrinal Tumors: Molecular Events & Therapeutic Implications: 1. Angiogenesis: vHL GeneOxygenationHypoxia +++ VEGFAngiogenesis PFS 96% 68% Bevacizumab + Octreotid LAR INF + Octreotid LAR

Neuroendocrinal Tumors: Molecular Events & Therapeutic Implications: 2. mTOR Inhibitor: Mammalian Target of Rapamycin Cellular Growth Protein Synthesis Autophagy Resistance to Apoptosis ++ Proliferation Altered Metabolism

RAD 001 (Everolimus): PR 13% SD 74%. DP 13%. Neuroendocrinal Tumors: Molecular Events & Therapeutic Implications: 2. mTOR Inhibitor:

RADIANT – 1 Neuroendocrinal Tumors: Molecular Events & Therapeutic Implications: 2. mTOR Inhibitor: Advanced Chemo-Resistant Neuroendocrinal Tumors RAD001 Octreotid LAR Radiological Response: 77% 84% PFS: 9.7 ms ms. > 50% reduction in > 50% of Patients

Quiz?? AdenocarcinomaNET

Final Take Home Message: NET not rare. Surgery is the Cornerstone in Curative Management. Serum Biomarkers Are Still There to Share. Tissue Markers Should be more Highlighted. Molecular Targeted Therapies are The Hope for Tomorrow.